Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
African Discovery Group announces signing of Definitive Sales and Purchase Agreement for Butembo Copper Asset in the Democratic Republic of Congo; name change to Copper Intelligence, Inc
Saga Metals Acknowledges U.S. Strategic Critical Minerals Reserve "Project Vault" and Highlights Titanium's Strategic Importance to North American Defense Supply Chains
Blackrock Silver to Present at the Precious Metals and Critical Minerals Virtual Investor Conference on February 10th 2026
